Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 7684 results

  1. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 08 January 2025

    Technology appraisal guidance
    In development

  2. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  3. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  4. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  5. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: 22 January 2025

    Technology appraisal guidance
    In development

  7. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  8. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Delgocitinib for treating moderate to severe chronic hand eczema ID6408

    In development [GID-TA11506] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Digital support for children and young people with eating disorders:early value assessment

    Awaiting development [GID-HTE10058] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  12. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  13. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 05 March 2025

    Highly specialised technologies guidance
    In development

  14. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 09 January 2025

    Interventional procedures guidance
    In development

  15. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development